| scholarly article | Q13442814 |
| P2093 | author name string | Valerie Smith | |
| Charles P Semba | |||
| Jodi Luchs | |||
| Robert Latkany | |||
| Joseph Martel | |||
| Aparna Raychaudhuri | |||
| Joseph Tauber | |||
| Kenneth Sall | |||
| OPUS-2 Investigators | |||
| Paul Karpecki | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lifitegrast | Q23044263 |
| eye disease | Q3041498 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 2423-2431 | |
| P577 | publication date | 2015-09-10 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | |
| P478 | volume | 122 |
| Q100558870 | A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation |
| Q92905263 | Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications |
| Q48019769 | An efficient synthesis of 6-arylbenzo[4,5]imidazo[2,1-a]isoquinolines via sequential α-arylation of carbonyl and deacylation catalyzed by CuI. |
| Q48095233 | Current Anti-Integrin Therapy for Ocular Disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q90825369 | Dengue drug discovery: Progress, challenges and outlook |
| Q26746232 | Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease |
| Q39404635 | Dry Eye Management: Targeting the Ocular Surface Microenvironment. |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q36252489 | Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment |
| Q33585580 | Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve |
| Q26740643 | Immunomodulation on the ocular surface: a review |
| Q41670949 | Integrins as Therapeutic Targets: Successes and Cancers. |
| Q39025675 | LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease |
| Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
| Q45037685 | Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials |
| Q38608475 | Lifitegrast for the treatment of dry eye disease in adults |
| Q33739879 | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| Q26774853 | Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease |
| Q37591609 | Lifitegrast: A novel drug for treatment of dry eye disease |
| Q93137705 | Lifitegrast: a novel drug for patients with dry eye disease |
| Q64106425 | Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity |
| Q47268214 | Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs |
| Q49261503 | Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. |
| Q37610134 | Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. |
| Q52661549 | Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. |
| Q36877000 | Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study |
| Q92236526 | Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review |
| Q89349313 | Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast |
| Q90351231 | The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options |
| Q47424328 | Update in Current Diagnostics and Therapeutics of Dry Eye Disease. |
| Q50039889 | [Novel current and future therapy options for treatment of dry eye disease]. |
Search more.